Regressive mutations in KRAS and SMAD4, as well as specific ERBB2 point mutations, have been shown to influence tumor growth kinetics, metastatic behavior, and responsiveness to targeted or cytotoxic agents [24,25]. This evidence concerns the gene ERBB2 and neoplasm.